Eli Lilly Gross Margin 2010-2024 | LLY

Current and historical gross margin for Eli Lilly (LLY) over the last 10 years. The current gross profit margin for Eli Lilly as of March 31, 2024 is %.
Eli Lilly Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2024-03-31 $35.93B $28.80B 80.16%
2023-12-31 $34.12B $27.04B 79.25%
2023-09-30 $32.07B $25.23B 78.67%
2023-06-30 $29.52B $22.96B 77.77%
2023-03-31 $27.69B $21.51B 77.67%
2022-12-31 $28.54B $21.91B 76.77%
2022-09-30 $29.24B $22.11B 75.61%
2022-06-30 $29.07B $22.09B 75.98%
2022-03-31 $29.32B $21.82B 74.40%
2021-12-31 $28.32B $21.01B 74.18%
2021-09-30 $27.76B $20.78B 74.84%
2021-06-30 $26.73B $19.85B 74.26%
2021-03-31 $25.49B $19.34B 75.88%
2020-12-31 $24.54B $19.06B 77.65%
2020-09-30 $23.21B $18.17B 78.26%
2020-06-30 $22.95B $18.06B 78.67%
2020-03-31 $23.09B $18.29B 79.22%
2019-12-31 $22.32B $17.60B 78.85%
2019-09-30 $21.84B $17.28B 79.09%
2019-06-30 $21.67B $17.13B 79.03%
2019-03-31 $21.62B $16.97B 78.47%
2018-12-31 $21.49B $16.81B 78.22%
2018-09-30 $19.12B $15.63B 81.72%
2018-06-30 $19.47B $15.54B 79.83%
2018-03-31 $19.71B $15.45B 78.37%
2017-12-31 $19.97B $15.53B 77.73%
2017-09-30 $22.47B $16.44B 73.18%
2017-06-30 $22.01B $16.16B 73.45%
2017-03-31 $21.59B $15.85B 73.43%
2016-12-31 $21.22B $15.51B 73.09%
2016-09-30 $20.84B $15.26B 73.23%
2016-06-30 $20.61B $15.19B 73.72%
2016-03-31 $20.18B $15.01B 74.39%
2015-12-31 $19.96B $14.92B 74.75%
2015-09-30 $19.71B $14.80B 75.12%
2015-06-30 $19.62B $14.69B 74.86%
2015-03-31 $19.58B $14.68B 74.96%
2014-12-31 $19.62B $14.68B 74.85%
2014-09-30 $20.30B $15.24B 75.04%
2014-06-30 $21.20B $16.20B 76.43%
2014-03-31 $22.20B $17.22B 77.59%
2013-12-31 $23.11B $18.21B 78.77%
2013-09-30 $23.26B $18.49B 79.50%
2013-06-30 $22.93B $18.16B 79.18%
2013-03-31 $22.60B $17.85B 78.96%
2012-12-31 $22.60B $17.81B 78.78%
2012-09-30 $22.69B $17.82B 78.54%
2012-06-30 $23.40B $18.39B 78.61%
2012-03-31 $24.05B $18.96B 78.85%
2011-12-31 $24.29B $19.22B 79.13%
2011-09-30 $24.43B $19.45B 79.62%
2011-06-30 $23.93B $19.31B 80.66%
2011-03-31 $23.43B $19.01B 81.12%
2010-12-31 $23.08B $18.71B 81.08%
2010-09-30 $22.82B $18.26B 79.99%
2010-06-30 $22.73B $18.10B 79.63%
2010-03-31 $22.28B $17.72B 79.56%
2009-12-31 $21.84B $17.59B 80.55%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $847.248B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $631.845B 48.55
Johnson & Johnson (JNJ) United States $350.533B 13.92
Merck (MRK) United States $324.174B 58.98
AbbVie (ABBV) United States $302.599B 15.64
AstraZeneca (AZN) United Kingdom $243.139B 21.14
Novartis AG (NVS) Switzerland $214.497B 15.21
Pfizer (PFE) United States $155.321B 19.30
Sanofi (SNY) $119.456B 11.27
Innoviva (INVA) United States $1.013B 7.11